recent updates on tp53 mutation in cll
Published 2 years ago • 754 plays • Length 3:08Download video MP4
Download video MP3
Similar videos
-
2:36
current knowledge of the tp53 mutation and its role in cll
-
3:13
tp53 mutations in cll: a large retrospective analysis
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
2:01
the evolution of bcl2 inhibition in cll
-
1:21
identifying low-burden tp53 mutations with ngs in cll
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
18:58
pd-l1 testing by immunohistochemistry
-
8:14
progress in the treatment of tp53 mutated aml
-
16:56
p53 mutations in cancer
-
2:45
safety and efficacy of inotuzumab ozogamicin conditioning for allosct in lymphoid malignancies
-
3:09
overcoming challenges with targeted therapies for cll: high-risk mutations and btki resistance
-
4:31
the impact of high and low burden tp53 mutations on risk and treatment decision in cll
-
1:26
updates in the treatment landscape of p53-mutated aml/mds
-
1:07
testing for ighv and tp53 mutations to guide treatment decisions in cll
-
1:43
extended follow-up of the alpine trial: superior outcomes with zanubrutinib in r/r cll/sll
-
2:27
the importance of tp53 & ighv testing before treatment initiation in cll
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
1:38
the importance of tp53 in cll
-
2:14
the importance of tp53 testing in cll